{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:45:00Z","timestamp":1790023500350,"version":"4.0.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Real-world data regarding the use of dupilumab in children with atopic dermatitis (AD) are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the real-world efficacy of dupilumab in children with moderate-to-severe AD over an extended follow-up period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective study of patients (\u2264 18\u2005years) with moderate-to-severe AD treated with dupilumab in four Israeli tertiary centres. Efficacy and safety were assessed using descriptive statistics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 230 patients were included in the analysis [age 9.9\u2005years (SD 4.3), male\/female 1 : 1 ratio)]. Of them, 59.6% (137\/230) had \u2265 1 atopic comorbidity. The follow-up duration ranged from 2 to 248 weeks, with a median of 52 weeks (interquartile range 24\u201396). Within 12 weeks of treatment, 41.7% (68\/163) of patients had reached Investigator Global Assessment 0\u20131. The mean body surface area was reduced from 58.0% (SD 20.5%) at baseline to 27.8% (SD 20.2%) at 12 weeks. The average Pruritus Numeric Rating Scale score was reduced from 7.9 (SD 2.2) at baseline to 2.3 (SD 2.8) at 12 weeks. Adverse events, in 210 patients, included conjunctivitis in 34 patients (16.2%), injection-site reactions in 11 patients (5.2%) and dupilumab-associated head and neck dermatitis in 6 patients (2.9%). Overall, 26 of 210 patients (12.3%) discontinued the treatment: 9 of the 26 patients (35%) because of adverse events and 15 patients (58%) because of inadequate efficacy. The overall probability of dupilumab survival at 52 weeks was 94.0%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Real-world data presented here for 230 paediatric and adolescents with moderate-to-severe AD reinforce dupilumab\u2019s efficacy and safety and highlight dupilumab\u2019s high survival rate after 1\u2005year of treatment in the paediatric population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae406","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T16:05:14Z","timestamp":1731600314000},"page":"372-379","source":"Crossref","is-referenced-by-count":7,"title":["Real-world efficacy and safety of dupilumab for paediatric atopic dermatitis: a multicentre retrospective study"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5149-9277","authenticated-orcid":false,"given":"Eitan","family":"Pirov","sequence":"first","affiliation":[{"name":"Pediatric Dermatology Unit, Department of Dermatology, Sheba Medical Center ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered","family":"Molho-Pessach","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hebrew University of Jerusalem, Pediatric Dermatology Service, Department of Dermatology, Hadassah Medical Center , Jerusalem ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Cohen-Barak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Emek Medical Center , Afula ,","place":["Israel"]},{"name":"Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen A","family":"Barak Levitt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Emek Medical Center , Afula ,","place":["Israel"]},{"name":"Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviv","family":"Barzilai","sequence":"additional","affiliation":[{"name":"Pediatric Dermatology Unit, Department of Dermatology, Sheba Medical Center ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Renert-Yuval","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Pediatric Dermatology Unit, Schneider Children's Medical Center of Israel , Petah Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Bar-Ilan","sequence":"additional","affiliation":[{"name":"Pediatric Dermatology Unit, Department of Dermatology, Sheba Medical Center ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rivka","family":"Friedland","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Pediatric Dermatology Unit, Schneider Children's Medical Center of Israel , Petah Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8308-2790","authenticated-orcid":false,"given":"Shoshana","family":"Greenberger","sequence":"additional","affiliation":[{"name":"Pediatric Dermatology Unit, Department of Dermatology, Sheba Medical Center ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"2025012715574590300_llae406-B1","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.3390\/jcm12165409","article-title":"Treatment with methotrexate in infants and toddlers with atopic dermatitis: a retrospective multi-center study","volume":"12","author":"Barak Levitt","year":"2023","journal-title":"J Clin Med"},{"key":"2025012715574590300_llae406-B2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025012715574590300_llae406-B3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.anai.2012.10.005","article-title":"Atopic dermatitis in a high-risk cohort: natural history, associated allergic outcomes, and risk factors","volume":"110","author":"Carlsten","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025012715574590300_llae406-B4","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2147\/DDDT.S281626","article-title":"The application of dupilumab to pediatric patients aged 6-11yrs with moderate-to-severe atopic dermatitis whose disease is not adequately controlled: the clinical data so far","volume":"17","author":"Balboul","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"2025012715574590300_llae406-B5","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jaip.2022.06.014","article-title":"Dupilumab improves clinical scores in children and adolescents with moderate to severe atopic dermatitis: a real-world, single-center study","volume":"10","author":"Pagan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025012715574590300_llae406-B6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/09546634.2018.1508816","article-title":"The use of methotrexate for treating childhood atopic dermatitis: a multicenter retrospective study","volume":"30","author":"Taieb","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"2025012715574590300_llae406-B7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.anai.2009.10.002","article-title":"From atopic dermatitis to asthma: the atopic march","volume":"105","author":"Spergel","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025012715574590300_llae406-B8","doi-asserted-by":"crossref","first-page":"e13887","DOI":"10.1111\/pai.13887","article-title":"Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry","volume":"33","author":"Kamphuis","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"2025012715574590300_llae406-B9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2040622318773686","article-title":"Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy","volume":"9","author":"Ari\u00ebns","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"2025012715574590300_llae406-B10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/12034754221130969","article-title":"Treatment with dupilumab in patients with atopic dermatitis: systematic review and meta-analysis","volume":"26","author":"Koskeridis","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"2025012715574590300_llae406-B11","doi-asserted-by":"crossref","first-page":"e15588","DOI":"10.1111\/dth.15588","article-title":"A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis","volume":"35","author":"Napolitano","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025012715574590300_llae406-B12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40272-021-00459-x","article-title":"Laboratory safety of dupilumab in patients aged 6-11\u2005years with severe atopic dermatitis: results from a phase III clinical trial","volume":"23","author":"Paller","year":"2021","journal-title":"Paediatr Drugs"},{"key":"2025012715574590300_llae406-B13","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11\u2005years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025012715574590300_llae406-B14","doi-asserted-by":"crossref","first-page":"adv00504","DOI":"10.2340\/00015555-3848","article-title":"Dupilumab provides significant clinical benefit in a phase 3 trial in adolescents with uncontrolled atopic dermatitis irrespective of prior systemic immunosuppressant use","volume":"101","author":"Deleuran","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2025012715574590300_llae406-B15","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1111\/jdv.18450","article-title":"Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11\u2005years): data from a French multicentre retrospective cohort in daily practice","volume":"36","author":"Lasek","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025012715574590300_llae406-B16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ced\/llae013","article-title":"Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study","volume":"49","author":"Hosseini-Ashrafi","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2025012715574590300_llae406-B17","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/jdv.19409","article-title":"Dupilumab therapy in children aged 2-12\u2005years with uncontrolled moderate-to-severe atopic dermatitis: a Chinese real-world study","volume":"38","author":"Zhou","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025012715574590300_llae406-B18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/pde.15418","article-title":"Multicenter Canadian case series of pediatric patients less than 12\u2005years of age with moderate-to-severe atopic dermatitis treated with dupilumab","volume":"41","author":"Martinez-Cabriales","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"2025012715574590300_llae406-B19","doi-asserted-by":"crossref","first-page":"2246602","DOI":"10.1080\/09546634.2023.2246602","article-title":"A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11\u2005years","volume":"34","author":"Patruno","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2025012715574590300_llae406-B20","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/jdv.18141","article-title":"Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian real-world experience","volume":"36","author":"Stingeni","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025012715574590300_llae406-B21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40272-022-00531-0","article-title":"Dupilumab treatment in children aged 6-11\u2005years with atopic dermatitis: a multicentre, real-life study","volume":"24","author":"Napolitano","year":"2022","journal-title":"Paediatr Drugs"},{"key":"2025012715574590300_llae406-B22","first-page":"1175","article-title":"Efficacy and treatment satisfaction of different systemic therapies in children and adolescents with moderate-to-severe atopic dermatitis: a real-world study","volume":"12","author":"Kiefer","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"2025012715574590300_llae406-B23","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1111\/jdv.18648","article-title":"A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis","volume":"37","author":"Stingeni","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025012715574590300_llae406-B24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ad.2023.10.006","article-title":"Efficacy and safety of dupilumab for the treatment of severe atopic dermatitis in clinical practice: a single center experience","volume":"115","author":"Mart\u00ednez-Dom\u00e9nech","year":"2024","journal-title":"Actas Dermosifiliogr"},{"key":"2025012715574590300_llae406-B25","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/jdv.18109","article-title":"Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study","volume":"36","author":"Gu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025012715574590300_llae406-B26","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2020.05.102","article-title":"One-year real-world clinical effectiveness, safety, and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: a single-center retrospective study","volume":"84","author":"Uchida","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025012715574590300_llae406-B27","doi-asserted-by":"crossref","first-page":"e13979","DOI":"10.1111\/dth.13979","article-title":"Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients","volume":"33","author":"Dal Bello","year":"2020","journal-title":"Dermatol Ther"},{"key":"2025012715574590300_llae406-B28","first-page":"67","article-title":"Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: a real-world Canadian multicenter retrospective study","volume-title":"JAAD Int","author":"Georgakopoulos","year":"2021"},{"key":"2025012715574590300_llae406-B29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12016-022-08934-0","article-title":"Dupilumab-associated adverse events during treatment of allergic diseases","volume":"62","author":"Kychygina","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025012715574590300_llae406-B30","doi-asserted-by":"crossref","first-page":"23539","DOI":"10.1038\/s41598-021-02950-4","article-title":"A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world","volume":"11","author":"Jang","year":"2021","journal-title":"Sci Rep"},{"key":"2025012715574590300_llae406-B31","doi-asserted-by":"publisher","DOI":"10.4103\/singaporemedj.SMJ-2023-031","article-title":"Safety and efficacy of dupilumab in adult atopic dermatitis in Singapore","author":"Yew","year":"2024","journal-title":"Singapore Med J"},{"key":"2025012715574590300_llae406-B32","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","article-title":"Facial and neck erythema associated with dupilumab treatment: a systematic review","volume":"84","author":"Jo","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025012715574590300_llae406-B33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jaad.2019.06.026","article-title":"Characterizing dupilumab facial redness: a multi-institution retrospective medical record review","volume":"82","author":"Waldman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025012715574590300_llae406-B34","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1038\/s41467-024-46540-0","article-title":"Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells","volume":"15","author":"Bangert","year":"2024","journal-title":"Nat Commun"},{"key":"2025012715574590300_llae406-B35","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jaci.2016.04.053","article-title":"The skin microbiome is different in pediatric versus adult atopic dermatitis","volume":"138","author":"Shi","year":"2016","journal-title":"J Allergy Clin Immunol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae406\/60676800\/llae406.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/2\/372\/60676800\/llae406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/2\/372\/60676800\/llae406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T15:58:25Z","timestamp":1737993505000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/2\/372\/7900422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,11,14]]},"published-print":{"date-parts":[[2025,1,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae406","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,11,14]]}}}